Xixi Lin,Yongliang Jia,Xinwei Dong,Jian Shen,Yachao Jin,Yanyou Li,Fang Wang,Eitan Anenberg,Jiancang Zhou,Jianping Zhu,Xiaoping Chen,Qiangmin Xie,Yicheng Xie

Abstract:Diplatin, a Novel and Low-Toxicity Anti-Lung Cancer Platinum Complex, Activation of Cell Death in Tumors via a ROS/JNK/p53-Dependent Pathway, and a Low Rate of Acquired Treatment Resistance. By Lin, X., Jia, Y., Dong, X., Shen, J., Jin, Y., Li, Y., Wang, F., Anenberg, E., Zhou, J., Zhu, J., Chen, X., Xie, Q., Xie, Y. (2019) Frontiers in Pharmacology. 10:982. doi: 10.3389/fphar.2019.00982.In the original article, there was a mistake in Figure 3H as published. An incorrect image for the p53 measurement in A549 was shown. The corrected Figure 3H appears below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Correction to “New Pathway for Cisplatin Prodrug to Utilize Metabolic Substrate Preference to Overcome Cancer Intrinsic Resistance”

Erratum: Targeting NF-κB/AP-2β Signaling to Enhance Antitumor Activity of Cisplatin by Melatonin in Hepatocellular Carcinoma Cells.

Corrigendum for “A Novel Kinase Subverts Aluminium Resistance by Boosting Ornithine Decarboxylase‐dependent Putrescine Biosynthesis”

Correction To: Targeted Therapy for Cisplatin‐resistant Lung Cancer Via Aptamer‐guided Nano‐zinc Carriers Containing USP14 Sirna

Corrigendum: Discovery of Novel Doxorubicin Metabolites in MCF7 Doxorubicin-Resistant Cells

Corrigendum: Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K–AKT Pathway and Activating the AMPK–ROS Pathway

Correction to: Human drug efflux transporter ABCC5 confers acquired resistance to pemetrexed in breast cancer

Corrigendum: Receptor of advanced glycation end products deficiency attenuates cisplatin-induced acute nephrotoxicity by inhibiting apoptosis, inflammation and restoring fatty acid oxidation

Erratum: Exogenous glutathione contributes to cisplatin resistance in lung cancer A549 cells.

Corrigendum: Diplatin, a Novel and Low-Toxicity Anti-Lung Cancer Platinum Complex, Activation of Cell Death in Tumors Via a ROS/JNK/p53-Dependent Pathway, and a Low Rate of Acquired Treatment Resistance

Correction to: Dexamethasone-induced cisplatin and gemcitabine resistance in lung carcinoma samples treated ex vivo

Correction to “Folic acid-conjugated liposomal vincristine for multidrug resistant cancer therapy”

Correction: Enhancing the chemotherapeutic efficacy of platinum prodrug nanoparticles and inhibiting cancer metastasis by targeting iron homeostasis

Correction to: Metformin and Aspirin: Anticancer effects on A549 and PC3 cancer cells and the mechanisms of action

N6 -methyladenosine-induced ERRγ triggers chemoresistance of cancer cells through upregulation of ABCB1 and metabolic reprogramming: Erratum

Corrigendum: Regulation of microrna-497-targeting AKT2 influences tumor growth and chemoresistance to cisplatin in lung cancer

Correction: computational design, synthesis, and assessment of 3-(4-(4-(1,3,4-oxadiazol-2-yl)-1 H-imidazol-2-yl)phenyl)-1,2,4-oxadiazole derivatives as effective epidermal growth factor receptor inhibitors: a prospective strategy for anticancer therapy

Corrigendum: Chemoresistance and Metastasis in Breast Cancer Molecular Mechanisms and Novel Clinical Strategies

Correction: Infiltrating Mast Cells Increase Prostate Cancer Chemotherapy and Radiotherapy Resistances Via Modulation of P38/p53/p21 and ATM Signals.

Correction to: Cypripedin, a phenanthrenequinone from Dendrobium densiflorum, sensitizes non-small cell lung cancer H460 cells to cisplatin-mediated apoptosis

Corrigendum: Effective Delivery of siRNA-Loaded Nanoparticles for Overcoming Oxaliplatin Resistance in Colorectal Cancer